{
    "id": 20476,
    "fullName": "ALK L1196Q",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "ALK L1196Q lies within the protein kinase domain of the Alk protein (UniProt.org). L1196Q is predicted to confer a gain of function on the Alk protein as indicated by increased phosphorylation of Alk (PMID: 25749034) and has been demonstrated to confer resistance to Alk inhibitors in the context of NPM1-ALK in culture (PMID: 25749034, PMID: 23239810).",
            "references": [
                {
                    "id": 1807,
                    "pubMedId": 23239810,
                    "title": "Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23239810"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "L1196Q",
    "createDate": "03/29/2016",
    "updateDate": "09/06/2018",
    "referenceTranscriptCoordinates": {
        "id": 102060,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29220764A>T",
        "cDna": "c.3587T>A",
        "protein": "p.L1196Q",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5504,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing ALK L1196Q were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20952,
                "profileName": "NPM1 - ALK ALK L1196Q"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5503,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ASP3026 inhibited growth of human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing the crizotinib-resistant mutation ALK L1196Q in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20952,
                "profileName": "NPM1 - ALK ALK L1196Q"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20951,
            "profileName": "ALK L1196Q",
            "profileTreatmentApproaches": [
                {
                    "id": 8521,
                    "name": "ALK Inhibitor",
                    "profileName": "ALK L1196Q"
                }
            ]
        },
        {
            "id": 20952,
            "profileName": "NPM1 - ALK ALK L1196Q",
            "profileTreatmentApproaches": [
                {
                    "id": 16859,
                    "name": "ASP3026",
                    "profileName": "NPM1 - ALK ALK L1196Q"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102060,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29220764A>T",
            "cDna": "c.3587T>A",
            "protein": "p.L1196Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}